Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Nuo Therapeutics, Inc.v237263_ex99-1.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
______________
 
FORM 8-K
______________
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  October 14, 2011
 
______________
 
Cytomedix, Inc.
(Exact name of registrant as specified in its charter)
______________
 
 
Delaware
01-32518
23-3011702
(State or Other Jurisdiction
(Commission
(I.R.S. Employer
of Incorporation)
File Number)
Identification No.)

209 Perry Parkway, Suite 7, Gaithersburg, MD 20877
(Address of Principal Executive Office) (Zip Code)
 
240-499-2680
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
 
Item 7.01    Regulation FD Disclosure
 
           Attached, as Exhibit 99.1, is the press release issued in connection with the matter set forth under Item 8.01 below. The information in Exhibit 99.1 is not “filed” pursuant to the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any Securities Act registration statements. Additionally, the submission of this report on Form 8-K is not an admission as to the materiality of any information in this report that is required to be disclosed solely by Regulation FD.
 
Item 8.01    Other Events
 
Effective October 14, 2011, Cytomedix, Inc. (the “Company”) executed an option  agreement with a third party granting exclusive negotiating rights through December 31, 2011 to obtain a license from the Company to the marketing clearance authorization for AutoloGel System and its successor products and the supply of such products.   The third party agreed to make a non-refundable payment in the amount of $2 million within 15 days of execution of the option agreement. Any final agreement remains subject to the successful conclusion of due diligence and negotiation between the parties and there can be no assurance that the parties will be successful in executing a definitive license agreement.
 
Item 9.01    Financial Statement and Exhibits
 
(d)  Exhibits.
 
99.1  Press release.
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 

         
Cytomedix, Inc.
   
  
     
 
By:  
/s/ Martin P. Rosendale  
   
Martin P. Rosendale
Chief Executive Officer
   
 
Date:  October 17, 2011